---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-011077"
form_type: "8-K"
ticker: "MTNB"
cik: "0001582554"
company_name: "Matinas BioPharma Holdings, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:28:15.546700+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Matinas BioPharma oral LNC-docetaxel shows no toxicity in mouse study; 8x higher dose tolerated without weight loss

## Summary
- Total docetaxel delivered orally via LNC was >8x IV dose by Day 22; all IV mice lost avg 20% weight, LNC mice maintained weight normal.
- One IV-docetaxel mouse died (32% weight loss); LNC-docetaxel mice had no mortality and weight statistically same as saline controls.
- Daily oral LNC-docetaxel dose 50% higher and total drug 3.5x greater than prior study that showed comparable anti-tumor activity to IV-docetaxel.
- Company plans further evaluation of higher doses in additional tumors and other toxic chemotherapies using LNC platform.

## SEC filing metadata
- accession: 0001493152-24-011077
- form_type: 8-K
- ticker: MTNB
- cik: 0001582554
- company_name: Matinas BioPharma Holdings, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1582554/000149315224011077/0001493152-24-011077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1582554/000149315224011077/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-011077
- JSON: https://secwatch.observer/filing/0001493152-24-011077.json
- Plain text: https://secwatch.observer/filing/0001493152-24-011077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.